US Patent Issued for Drug Encapsulation Applications of MIV Therapeutics' Biocompatible Drug Eluting Coating Technology
***
VANCOUVER, June 1 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB) is pleased to announce today that the United States Patent and Trademark Office has awarded The University of British Columbia (UBC) a patent relating to MIVT's licensed biocompatible hydroxypatite (HAp) coating technology. MIVT has the exclusive worldwide license from UBC to use and sublicense the HAp coating technologies for the development, manufacture and sale of coated stents and other implantable medical devices as drug delivery systems. The newly issued patent entitled "Biofunctional Hydroxyapatite Coatings and Microspheres for In-Situ Drug Encapsulation" relates to MIV Therapeutics' platform HAp technology which is currently being developed as the next generation of biocompatible coatings for drug eluting cardiovascular stents and for medical device drug delivery systems. "The issuance of this patent covering our platform HAp coating technology is a historical event for MIVT," said Chairman, President and CEO Alan Lindsay. "Recently, we have been releasing very positive news from all of our preclinical testing. Preliminary test results have been exceeding our expectations. With this expansion in our intellectual property portfolio, MIVT's biocompatible HAp coating technology for passive and drug eluting applications has the potential to make a significant impact to medical science as an attractive alternative to polymeric coatings currently being developed by the industry." The US patent, No. 6,730,324, relates to the unique method of obtaining HAp for coatings and microspheres that encapsulate drugs for therapeutic use and their subsequent controlled release. The inventors on this patent include Dr. Tom Troczynski, MIVT Vice President, Coating Technologies and UBC Professor, Dean Mo Liu and Quanzu Yang, both of UBC. The European Patent Office has also advised MIV Therapeutics and University of British Columbia that the patent application entitled "Biofunctional Hydroxyapatite Coatings and Microspheres for In-Situ Drug Encapsulation" has been declared in suitable form to grant the European patent. Dr. Troczynski commented, "The encapsulation of therapeutic agents in 100% biocompatible and bio-resorbable porous calcium phosphates, in particular microporous hydroxyapatite, is a leading edge technology for drug delivery systems. MIV Therapeutics' exclusive license for these technologies strengthens the Company's technological advantage in the highly competitive market of medical devices." The drug-eluting HAp technology covered by the issued patent is being developed in collaboration with UBC under a Collaborative Research Agreement and is funded in part by a Collaborative Research and Development Grant awarded by the Natural Sciences and Engineering Council of Canada (NSERC). The recently issued patents relate to the use of HAp for drug encapsulation and controlled release. About MIV Therapeutics MIV Therapeutics is developing a "next generation" line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIV's ultra-thin coating has been designed to inhibit inflammatory response and restenosis. The drug-eluting HAp technology is being developed in collaboration with UBC under a Collaborative Research Agreement and is funded in part by a Collaborative Research and Development Grant awarded by the Natural Sciences and Engineering Council of Canada (NSERC). MIVT's manufacturing facility meets the guidelines applicable to CE Mark, FDA and GMP requirements. Please visit www.mivtherapeutics.com for more information. About The University of British Columbia The University of British Columbia located in the Pacific Rim gateway of Vancouver, Canada, ranks in the top 10 of North American universities in technology licensing and commercialization, and generates more U.S. patents than any other Canadian public institution. Product inquiries and business opportunities: Arc Rajtar arajtar@mivi.ca (604) 301-9545 ext 22 Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe", "will", "breakthrough", "significant", "indicated", "feel", "revolutionary", "should", "ideal", "extremely" and "excited". These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. For Further Information Contact: Dan Savino MIV Therapeutics Ph:1 800 221-5108 ex.16 dsavino@mivi.ca Richard Cooper/Stan Altschuler Strategic Growth International Inc. (212) 838-1444 info@sgi-ir.com SOURCE MIV Therapeutics Inc. -0- 06/01/2004 /CONTACT: Dan Savino, MIV Therapeutics, Ph: 1 800 221-5108 ex.16, dsavino@mivi.ca; Richard Cooper/Stan Altschuler, Strategic Growth International Inc., (212) 838-1444, info@sgi-ir.com/ (MIVT) CO: MIV Therapeutics Inc. ST: British Columbia IN: MTC OTC SU: -30-
------------------ Due Da Due......But Be Quick About It!!!!!
posted
What's causing this thing to not really move? When IVOC receives patents, the thing goes ballistic.
Posts: 395 | From: Grand Rapids MI 49546 | Registered: Feb 2004
| IP: Logged |
posted
I was able to fill for 0.41 today! This company sounds very good, if not in the short term, the long term looks bright. Excellent pick dardadog! Like always.
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
posted
*pulls trigger* If only I would learn to listen to more of dardadog's picks!! Had this baby in my watch list...and now sitting here watching the train fly by.
Posts: 372 | From: Belleview, FL, USA | Registered: Apr 2004
| IP: Logged |
To-date The University of British Columbia has filed 3 patent applications on the novel coating technologies that MIVT intends to use for its stent coating and for other medical devices. Under the license agreement with UBC, the Company (MIVT) has the 'exclusive', 'worldwide' rights to the coatings technologies covered by these patents, including the rights to manufacture and market coated products using these technologies.
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
posted
MIV Therapeutics Inc. Retains Strategic Growth as Investor Relations Advisor via COMTEX
June 10, 2004
VANCOUVER, Jun 10, 2004 /PRNewswire-FirstCall via COMTEX/ --
MIV Therapeutics Inc. (MIVT:OTCBB) a company developing the next generation of coatings for drug delivery on stents and medical devices is pleased to announce it has retained the services of Strategic Growth International Inc. (SGI), to provide global exposure to the investment community.
"In an effort to gain recognition among institutional investors and retail buyers, we are pleased to enlist the services of SGI to facilitate an ambitious market awareness program for MIVT," said Chairman, President and CEO Alan Lindsay. "We look forward to working with SGI to implement investor relations initiatives as our company reaches significant development milestones ahead. With our current progress and achievements we believe the timing is appropriate to garner the support of the institutional investment community".
Founded in 1989, SGI is headed by Richard Cooper and Stanley Altschuler, two long-time and highly respected Wall Street veterans, who have assembled an experienced team of investment/financial professionals. Since its inception in 1989, Strategic Growth has achieved an unparalleled level of excellence and success, particularly in the biotechnology and health services sectors.
Leading this account for SGI is, Richard E. Cooper, Chairman and co- founder of Strategic Growth International, Inc. Prior to his co-founding SGI, Mr. Cooper was a Managing Director at Salomon Brothers for five of his 14 years at the firm.
About MIV Therapeutics
MIV Therapeutics is developing a "next generation" line of advanced biocompatible hydroxyapatite coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIV's ultra- thin coating has been designed to inhibit inflammatory response and restenosis.
The drug-eluting HAp technology is being developed in collaboration with UBC under a Collaborative Research Agreement and is funded in part by a Collaborative Research and Development Grant awarded by the Natural Sciences and Engineering Council of Canada (NSERC).
MIVT's manufacturing facility meets the guidelines applicable to CE Mark, FDA and GMP requirements. Please visit www.mivtherapeutics.com for more information.
Forward-Looking Statements: The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Actual results may differ materially depending on a variety of factors. For Further Information Contact: Dan Savino Richard Cooper/Jennifer K. Zimmons, Ph.D. MIV Therapeutics Inc. Strategic Growth International Inc. Ph: 1 800 221-5108 ex.16 (212) 838-1444 dsavino@mivi.ca info@sgi-ir.com SOURCE MIV Therapeutics Inc.
Dan Savino, MIV Therapeutics Inc., Ph: 1-800-221-5108 ex.16, dsavino@mivi.ca; Richard Cooper/Jennifer K. Zimmons, Ph.D., Strategic Growth International Inc., (212) 838-1444, info@sgi-ir.com (MIVT)
Copyright (C) 2004 PR Newswire. All rights reserved.
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
VANCOUVER, Jun 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)
MIV Therapeutics Inc. (MIVT:OTCBB), announced today that its proprietary Hydroxyapatite (HAp) ultra-thin "passive" stent coating has successfully passed the Rabbit Pyrogen Test (Material Mediated) - ISO confirming that the coating is non-pyrogenic and does not induce fever.
Biocompatibility is one of the key features that differentiate MIVT's proprietary HAP coating technology. Dr. Tom Troczynski, MIVT's Vice President of Coatings commented, "There is an extensive range of biocompatibility tests performed on cardiovascular stents coated with our proprietary coating technology that include a variety of short and long term assessments. In their totality, this range of tests is expected to confirm total biocompatibility of our proprietary HAp coating technologies. The Pyrogen test result proved that HAp does not induce fever when injected into the blood system and once again this result is in line with our long-standing expectations regarding total biocompatibility of our HAp coating material which is at the heart of our technologies."
The Rabbit Pyrogen (Material Mediated) - ISO Test was performed by Toxikon Corporation in Bedford, Massachusetts, USA. Dr. Kathleen Krenzer, O.D., Ph.D., who supervised this test, summarized in the final report: "The extract of the test article, Hydroxyapatite (HAp) coated stent, was evaluated for its potential to produce a pyrogenic response (induce fever - MIVT comment) when tested in rabbits. Based upon the criteria of the protocol, the test article meets the requirements of the Pyrogen Test and is, therefore, considered non-pyrogenic."
The Pyrogen Test was designed to determine the presence of chemical pyrogens in extracts of solid materials in order to limit risks of febrile reaction in a patient. The test involved measuring the rise in temperature of New Zealand White rabbits following the intravenous injection of a test article. New Zealand White rabbits have been used for pyrogen evaluation studies in line with ISO 10993-11 guidelines. The test and control article was injected into the ear vein of rabbits, and the body temperature of animals was monitored back-to-back with control articles. The study conformed to all applicable laws and regulations, including ISO 10993-11: 1993 standard for "Biological Evaluation of Medical Devices - Part 11 "Tests for Systemic Toxicity", ISO 17025: 1999 "General Requirements for the Competence of Testing and Calibration Laboratories" and ISO 10993-12: 1992 standard "Biological Evaluation of Medical Devices" - Part 12, "Sample Preparation and Reference Materials", and met the requirements of the Good Laboratory Practices (GLP) 21 CFR, Part 58 set by the U.S. Food and Drug Administration, and complied with general CE Mark Application requirements.
Alan Lindsay, CEO of MIVT stated "As we progress through our R&D program, all preliminary test results continue to support our firm belief that the Company's proprietary HAp ultra-thin coating exhibits properties that provide our technology with a clear competitive advantage. We persist in our drive towards making our unique, biocompatible HAp ultra-thin coating the "coating of choice" for cardiovascular stents and a broad range of future medical devices."
About Toxikon Corp.
"Toxikon Corp. (ISO/IEC 17025:1999 certified) has been known for the past 25 years for excellence in medical device testing, toxicology and bio- analytical chemistry services. The Company provides comprehensive testing services to the biomaterials/medical device market, the pharmaceutical and biotechnology industry. Toxikon Corporation's testing services include biocompatibility testing, toxicology, pharmacology, metabolism, bioanalysis, pharmaceutical analysis, and biosafety testing. A leader in the industry, the company's professional expertise along with a recognized stature in the industry provides Toxikon Corporation a unique capability to assist clients in the successful completion off their registration."
About MIV Therapeutics
MIV Therapeutics is developing a "next generation" line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIV's ultra-thin coating has been designed to inhibit inflammatory response and restenosis.
The drug-eluting HAp technology is being developed in collaboration with UBC under a Collaborative Research Agreement and is funded in part by a Collaborative Research and Development Grant awarded by the Natural Sciences and Engineering Council of Canada (NSERC).
MIVT's manufacturing facility meets the guidelines applicable to CE Mark, FDA and GMP requirements. Please visit www.mivtherapeutics.com for more information.
Investor Inquiries: Dan Savino Richard Cooper/Jennifer K. Zimmons, Ph.D. Investor Relations, Strategic Growth International Inc. MIV Therapeutics Inc. Ph: 212 838-1444 Ph: 1 800 221-5108 ex.16 Email: info@sgi-ir.com Fax: 604 301-9546 Email: dsavino@mivi.ca Product inquiries and business opportunities: Arc Rajtar arajtar@mivi.ca (604) 301-9545 ext 22
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
posted
This stock does not have much volume going on, but they been quite consitent with their PRs and company updates. I consider this as a long term investment.
Latest News:
MIV Therapeutics' Coatings Presented at World Biomaterials Congress via COMTEX
June 22, 2004
VANCOUVER, Jun 22, 2004 /PRNewswire-FirstCall via COMTEX/ --
MIV Therapeutics Inc. (MIVT:OTCBB), is proud to announce that its proprietary, biocompatible Hydroxyapatite (HAp) ultra- thin coating technology for passive and drug-eluting applications on cardiovascular stents and other implantable medical devices was presented by MIVT at the 7th World Biomaterials Congress in Sydney, Australia, May 17-21, 2004. World Biomaterials Congress events are conducted every 4 years, and attract top scientists, industry and medical professionals from around the World.
The MIVT was represented by Vice President of Coatings Dr. Tom Troczynski, Ph.D., Professor of Ceramics at The University of British Columbia and by MIV's V.P Operations, Arc Rajtar, MEng. Mr. Rajtar delivered an oral presentation titled "Nanoporous Calcium Phosphate Thin Coatings for Stents" that focused on cardiovascular applications of MIVT proprietary coating technologies. Dr. Troczynski presented a scientific poster "Mesoporous Bioglass Films by Sol-Gel" and delivered a presentation on "In-Situ Formation of Nano-dispersed Hydroxyapatite in Poly (propylene Fumarate) Matrix".
Alan Lindsay, CEO of MIVT stated, "We were very impressed by the high level of interest in our proprietary Hydroxyapatite coating technology from the professional community at this year's World Biomaterials Congress. This was the first time our biocompatible coating has been presented to a multinational audience at such a prestigious World-class event. The unique properties of our proprietary coating, when applied to the demanding environment of cardiovascular stents, place our research at the leading edge of new generation coating technologies. Our strategy is to continue to further expand evidence of our technology's validity and continue to progress methodically towards successful clinical application in our target markets."
Dr. Troczynski commented, "Our research and development now enters another critical stage which is expected to result in a truly biocompatible coating with flexible drug eluting properties potentially useful for numerous applications in the world of medical devices and implants. We continue to remain extremely optimistic about these possibilities which we believe will offer considerable opportunity to the medical field and to our investors, in general."
Mr. Rajtar added," The advantageous properties of our coating and its compliance with to a comprehensive range of biocompatibility studies highlight the strength of our coating material and the technologies used in its application. The presentations were delivered to an international symposium of scientists and industry professionals specializing in the medical device and the health care profession. The enthusiastic responses received following the presentations were extremely encouraging and rewarding."
For abstracts of MIVT presentations click on the below links:
1) "In-Situ Formation of Nano-dispersed Hydroxyapatite in Poly(propylene Fumarate) Matrix"
2) "Mesoporous Bioglass Films by Sol-Gel" 3) "Nanoporous Calcium Phosphate Thin Coatings for Stents"
About MIV Therapeutics
MIV Therapeutics is developing a "next generation" line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIV's ultra-thin coating has been designed to inhibit inflammatory response and restenosis. A Collaborative Research Agreement (CRA) between MIVI and the University of British Columbia received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of HAp as a drug eluting coating, and achieved the milestones for Phase I of the program by demonstrating the coating has excellent properties suitable for drug encapsulation and drug eluting purposes. MIVT's manufacturing facility meets the guidelines applicable to CE Mark, FDA and GMP requirements. Please visit www.mivtherapeutics.com for more information.
MIVT has developed a proprietary HAp stent coating in collaboration with UBC and has protected these collaborative technologies by supporting three patent applications applied by UBC. MIVT has the exclusive worldwide license from UBC to use and sublicense the HAp coating technologies for the development, manufacture and sale of coated stents and other implantable medical devices. Hydroxyapatite is a well-known, biocompatible, porous material that makes up bone mineral and the matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. Following the successful completion of the first stage of its research and development program, focusing on porous coatings for drug-elution purposes with financial support from the Natural Sciences and Engineering Research Council of Canada) the Company has progressed to the next development stage, which is expected to finalize the drug-eluting research and development program.
Investor Inquiries: Dan Savino Richard Cooper/Jennifer K. Zimmons, Ph.D. Investor Relations, Strategic Growth International Inc. MIV Therapeutics Inc. Ph: 212 838-1444 Ph: 1 800 221-5108 ex.16 Email: info@sgi-ir.com Fax: 604 301-9546 Email: dsavino@mivi.ca Product inquiries and business opportunities: Arc Rajtar arajtar@mivi.ca (604) 301-9545 ext 22
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
[This message has been edited by TradingWizard (edited June 22, 2004).]
posted
MIV Therapeutics Inc. Completes Significant Biocompatibility Milestones for HAp Stent Coating Technology via COMTEX
June 28, 2004
VANCOUVER, Jun 28, 2004 /PRNewswire-FirstCall via COMTEX/ --
MIV Therapeutics Inc. (OTCBB:MIVT), announced today that it has successfully completed the full range of biocompatibility studies on its proprietary, biocompatible hydroxyapatite (HAp) ultra-thin coating technology. The coating is designated for passive and drug-eluting application on cardiovascular stents and other implantable medical devices.
Toxikon Corporation, Bedford, MA, was commissioned by MIVT to perform the complete range of 12 biocompatibility tests which are summarized below:
------------------------------------------------------------------------- Study Focus Result ------------------------------------------------------------------------- Long Term Signs of toxicity PASS - HAp coated stent was Intramuscular found non-toxic when Implantation implanted for 13 weeks. (13 weeks) clinical ------------------------------------------------------------------------- Short Term Local symptoms PASS - HAp coated stent was Intramuscular of toxicity non toxic Implantation (2 weeks) ------------------------------------------------------------------------- Bone Marrow Damage to the PASS - HAp coated stent Micronucleous chromosomes considered non-mutagenic. Assay ------------------------------------------------------------------------- Chromosomal Structural changes PASS - HAp coated stent Aberration to the chromosomes considered non-clastogenic. ------------------------------------------------------------------------- Ames Assay / Reverse mutation PASS - HAp coated stent is Salmonella of histidine and not mutagenic in the test Typhorium and tryptophan genes species. Escherichia Coli Reverse Mutation Assay ------------------------------------------------------------------------- Hemolysis Effect on blood, PASS - HAp coated stent is elevated hemoglobin considered non-hemolytic. level, red cell destruction ------------------------------------------------------------------------- L929 MEM Elution Cellular response/ PASS - HAp coated stent reactivity considered non-cytotoxic. - cytotoxicity ------------------------------------------------------------------------- Intracutaneous Irritation after PASS - "HAp coated stent is Injection intracutaneous considered negligible injection irritant". ------------------------------------------------------------------------- Kligman Allergic potential PASS - HAp coated stent Maximization elicited no allergic reaction. ------------------------------------------------------------------------- Pyrogen Raise in body PASS - HAp coated stent is temperature considered non-pyrogenic. ------------------------------------------------------------------------- Systemic Injection Biological reaction PASS - HAp coated stent test triggered by considered negative. potential toxic effects ------------------------------------------------------------------------- 14-day Repeat Dose Systemic toxicity PASS - HAp coated stent was Intravenous after repetitive non-toxic. Toxicity Study intravenous injection ------------------------------------------------------------------------- In May 2003, MIVT's HAp coated stents successfully passed the key thrombogenicity study conducted to evaluate any evidence of clotting in the blood stream. The study, performed by Toxikon Corporation, concluded, "MIVT's HAp coated stents performed well, with minimal to no significant thrombosis, thus successfully meeting the scientific and regulatory requirements."
Alan Lindsay, CEO of MIVT, summarized, "The successful outcomes in the biocompatibility tests performed by a recognized independent organization that specialize in toxicology and bio-analytical chemistry services represents ultimate proof of the exceptional biocompatibility of our HAp coating. It reinforces our firm belief in the unique properties of our proprietary coating technologies and their suitability for use in cardiovascular stents and for other medical devices. We are determined to make our coating technology a success."
Dr. Tom Troczynski, Ph.D., Professor of Ceramics at The University of British Columbia and MIVT Vice President of Coatings stated, "Results of studies confirm our earlier expectations regarding the biocompatibility of our HAp coating technology. These results also confirm that our unique Hydroxyapatite coating carries considerable and increasing potential to become the coating of choice for passive and drug delivery applications on stents. We will continue to expand evidence of suitability of our coating technology for clinical applications. The completion of the 13-week-long trial titled "Long Term Intramuscular Implantation - Clinical" finalized the full range of biocompatibility studies performed on our proprietary HAp ultra-thin coating. All these studies were compliant with U.S. FDA 21 CFR, part 58 and Good Laboratory Practices regulations, in line with CE Mark and FDA requirements. The results of the biocompatibility studies on ultra-thin coating will be carried over to other potential applications of our multiplatform coating technologies. We achieved this critical milestone on time and on budget."
About Toxikon Corp.
"Toxikon Corp. (ISO/IEC 17025:1999 certified) has been known for the past 25 years for excellence in medical device testing, toxicology and bio- analytical chemistry services. The Company provides comprehensive testing services to the biomaterials/medical device market, the pharmaceutical and biotechnology industry. Toxikon Corporation's testing services include biocompatibility testing, toxicology, pharmacology, metabolism, bioanalysis, pharmaceutical analysis, and biosafety testing. A leader in the industry, the company's professional expertise along with a recognized stature in the industry provides Toxikon Corporation a unique capability to assist clients in the successful completion of their registration."
About MIV Therapeutics
MIV Therapeutics is developing a "next generation" line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIV's ultra-thin coating has been designed to inhibit inflammatory response and restenosis. A Collaborative Research Agreement (CRA) between MIVI and the University of British Columbia received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of HAp as a drug eluting coating, and achieved the milestones for Phase I of the program by demonstrating the coating has excellent properties suitable for drug encapsulation and drug eluting purposes. MIVT's manufacturing facility meets the guidelines applicable to CE Mark, FDA and GMP requirements. Please visit www.mivtherapeutics.com for more information.
MIVT has developed proprietary HAp stent coating in collaboration with UBC and has protected these collaborative technologies by financially supporting three patents. MIVT has the exclusive worldwide license from UBC to use and sublicense the HAp coating technologies for the development, manufacture and sale of coated stents and other implantable medical devices. Hydroxyapatite is a well-known, biocompatible, porous material that makes up bone mineral and the matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. Following the successful completion of the first stage of its research and development program, focusing on porous coatings for drug-elution purposes with financial support from the Natural Sciences and Engineering Research Council of Canada) the Company has progressed to the next development stage, which is expected to finalize the drug-eluting research and development program.
Investor Inquiries: Dan Savino Richard Cooper/Jennifer K. Zimmons, Ph.D. Investor Relations, Strategic Growth International, Inc. MIV Therapeutics Inc. Ph: 212 838 1444 Ph: 1 800 221 5108 ex. 16 Fax: 212 838 1511 Fax: 604 301 9546 Email: info@sgi-ir.com Email: dsavino@mivi.ca Product inquiries and business opportunities: Arc Rajtar arajtar@mivi.ca 604 301 9545 ex. 22 Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe", "will", "breakthrough", "significant", "indicated", "feel", "revolutionary", "should", "ideal", "extremely" and "excited". These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Copyright (C) 2004 MIV Therapeutics Inc. All rights reserved.
posted
MIV Therapeutics Gains 8.93% on 2X Average Volume
Jul 15, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (MIVT) gained 8.93% Tuesday to close at $0.305, on volume of 220,683, twice its average volume of 105,677.
MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated June 18.. SISM Research is distributed by the Investrend Research Syndicate.
Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adhere to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the Association for Investment Management and Research (http://www.aimr.org).
According to the New York Times (NYT), a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."
The fee for SISM coverage was $16,500, and the fees were paid by the company to SISM. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend Research affiliate platform, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp
posted
************.com: ************.com Reports on Stocks of Interest and Stocks on the Move for August 17, 2004. via COMTEX
August 17, 2004
Aug 17, 2004 (M2 PRESSWIRE via COMTEX) --
scans of moving stocks on the OTCBB and Pink Sheets revealed a short list of stocks on the move this morning. Volume is to light on the OTCBB today.
Among Stocks of interest today, MIV Therapeutics (OTCBB: MIVT) is up .11 to .33 so far this morning on volume of 268,000 shares traded. GameZnFlix, Inc. (OTCBB: GZFX) is up .004 to .04 on news today.
Details regarding these stocks as well as many other stocks of interest and stocks on the move can be found at http://www.************.com/stockpage.htm by 12:30 EDT each weekday.
About ************.com
************.com is a media and information site dealing with the OTCBB, Pink Sheets, AMEX and NASDAQ stock markets. ************.com produces quality and timely audio content that is unique and offers market participants and investors a different look at the markets. Audio interviews are regularly conducted with company officials as well as individuals associated with the stock markets. Market statistics and updates on individual stocks of interest are transmitted to ************.com subscribers daily via email and are posted at the web site at http://www.************.com by early afternoon each weekday.
************.com also assists publicly traded companies by providing consulting services, Investor Relations Services and a variety of financing options as well as availability of public trading shells. ************.com also assists privately owned companies with financing through reverse mergers.
************.com specializes in Investor Relations Services for newly merged companies and companies that are ready to go public.
The above news release may contain forward-looking statements and/or announcements. The list of stocks on ************.com`s "scans" and "stocks of interest" are for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities of the companies listed in this news release or on the web site at http://www.************.com.
************.com is a services and advertising company only. ************.com is not a licensed broker, broker dealer, market marker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing any stock of any company listed in news releases, interviewed and/or profiled at http://www.************.com. ************.com features interviews and profiles of publicly traded companies. In most cases we are compensated for the services rendered by a third party on behalf of the company.
************.com generally has no position in any company mentioned in this daily news release. However, ************.com`s principles and associates may have bought or may buy the shares of stocks that we profile/interview or list in news releases and may profit in the event those shares rise in value. At this time, ************.com owns no position in any company mentioned in this news release. ************.com received no compensation from any third party or company to mention any of the companies in this news release. ************.com regularly updates our disclaimer page and will post how many shares sold of any given stock that we have profiled or interviewed. Additionally, ************.com will not offer any opinion as to when others should sell; each investor must make that decision based on their own due diligence of the company.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Aug 17, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (MIVT) gained 22.22% Monday on Volume of 117,200, just under its average volume of 142,689, to close at $0.22.
MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated June 18.. SISM Research is distributed by the Investrend Research Syndicate.
Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adhere to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the Association for Investment Management and Research (http://www.aimr.org).
According to the New York Times (NYT), a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."
The fee for SISM coverage was $16,500, and the fees were paid by the company to SISM. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend Research affiliate platform, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.
FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
